A Trial In Patients With Advanced Cancer And Leukemia

• Status: Completed
• Trial end date: 2016-11-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available

• Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available

• Men and women >16 years old

Exclusion Criteria:

• Prior treatment with a gamma secretase inhibitor for treatment of cancer

• Patients taking Tamoxifen

• Patients with active graft versus host disease

• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness

• Patients who are pregnant or breast feeding

• Patients with clinical evidence of central nervous system disease